Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.

Bai RY, Esposito D, Tam AJ, McCormick F, Riggins GJ, Wade Clapp D, Staedtke V.

Gene Ther. 2019 Jun;26(6):277-286. doi: 10.1038/s41434-019-0080-9. Epub 2019 May 24.

PMID:
31127187
2.

Molecular Study of Thyroid Cancer in World Trade Center Responders.

van Gerwen MAG, Tuminello S, Riggins GJ, Mendes TB, Donovan M, Benn EKT, Genden E, Cerutti JM, Taioli E.

Int J Environ Res Public Health. 2019 May 7;16(9). pii: E1600. doi: 10.3390/ijerph16091600.

3.

Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1.

Pu W, Nassar ZD, Khabbazi S, Xie N, McMahon KA, Parton RG, Riggins GJ, Harris JM, Parat MO.

J Neurooncol. 2019 Jun;143(2):207-220. doi: 10.1007/s11060-019-03161-8. Epub 2019 Apr 4.

PMID:
30949900
4.

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.

Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT.

Nat Commun. 2019 Feb 26;10(1):943. doi: 10.1038/s41467-019-08905-8.

5.

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.

Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S.

Nature. 2018 Dec;564(7735):273-277. doi: 10.1038/s41586-018-0774-y. Epub 2018 Dec 12.

6.

Traps and trumps from adjacent-to-tumor samples in gastric cancer research.

de Assumpção PP, Khayat AS, Thomaz Araújo TM, Barra WF, Ishak G, Cruz Ramos AMP, Dos Santos SEB, Dos Santos ÂKCR, Demachki S, de Assumpção PB, Calcagno DQ, Dos Santos NPC, de Assumpção MB, Moreira FC, Dos Santos AMR, de Assumpção CB, Riggins GJ, Rodríguez Burbano RM.

Chin J Cancer Res. 2018 Oct;30(5):564-567. doi: 10.21147/j.issn.1000-9604.2018.05.10.

7.

Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Skibinski CG, Williamson T, Riggins GJ.

J Neurooncol. 2018 Dec;140(3):529-538. doi: 10.1007/s11060-018-03009-7. Epub 2018 Nov 9.

PMID:
30414098
8.

Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.

Svec RL, Furiassi L, Skibinski CG, Fan TM, Riggins GJ, Hergenrother PJ.

ACS Chem Biol. 2018 Nov 16;13(11):3206-3216. doi: 10.1021/acschembio.8b00864. Epub 2018 Nov 8.

9.

Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy.

Wilson KM, Mathews-Griner LA, Williamson T, Guha R, Chen L, Shinn P, McKnight C, Michael S, Klumpp-Thomas C, Binder ZA, Ferrer M, Gallia GL, Thomas CJ, Riggins GJ.

SLAS Technol. 2019 Feb;24(1):28-40. doi: 10.1177/2472630318803749. Epub 2018 Oct 5.

PMID:
30289729
10.

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ.

Neuro Oncol. 2019 Feb 14;21(2):189-200. doi: 10.1093/neuonc/noy146.

PMID:
30184215
11.

N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.

Zimmermann SC, Tichý T, Vávra J, Dash RP, Slusher CE, Gadiano AJ, Wu Y, Jančařík A, Tenora L, Monincová L, Prchalová E, Riggins GJ, Majer P, Slusher BS, Rais R.

J Med Chem. 2018 May 10;61(9):3918-3929. doi: 10.1021/acs.jmedchem.7b01792. Epub 2018 Apr 19.

PMID:
29648826
12.

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.

Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT.

Nat Commun. 2018 Mar 13;9(1):1057. doi: 10.1038/s41467-018-03476-6.

13.

GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity.

Barra WF, Moreira FC, Pereira Cruz AM, Khayat AS, Calcagno DQ, Carneiro Dos Santos NP, Mascarenhas Junior RW, Thomaz Araújo TM, Ishak G, Demachki S, Rodríguez Burbano RM, Campos Ribeiro Dos Santos ÂK, Batista Dos Santos SE, Riggins GJ, Pimentel de Assumpção P.

Oncotarget. 2017 Oct 31;8(61):104286-104294. doi: 10.18632/oncotarget.22216. eCollection 2017 Nov 28.

14.

Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.

Joshi AD, Botham RC, Schlein LJ, Roth HS, Mangraviti A, Borodovsky A, Tyler B, Joslyn S, Looper JS, Podell M, Fan TM, Hergenrother PJ, Riggins GJ.

Oncotarget. 2017 Jul 7;8(46):80124-80138. doi: 10.18632/oncotarget.19085. eCollection 2017 Oct 6.

15.

Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks.

Bai RY, Staedtke V, Xia X, Riggins GJ.

Oncotarget. 2017 Apr 18;8(16):25955-25962. doi: 10.18632/oncotarget.15427.

16.

Somatic retrotransposition is infrequent in glioblastomas.

Achanta P, Steranka JP, Tang Z, Rodić N, Sharma R, Yang WR, Ma S, Grivainis M, Huang CRL, Schneider AM, Gallia GL, Riggins GJ, Quinones-Hinojosa A, Fenyö D, Boeke JD, Burns KH.

Mob DNA. 2016 Nov 11;7:22. doi: 10.1186/s13100-016-0077-5. eCollection 2016.

17.

Correction: A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models.

Martinez NJ, Rai G, Yasgar A, Lea WA, Sun H, Wang Y, Luci DK, Yang SM, Nishihara K, Takeda S, Mohiuddin, Earnshaw I, Okada T, Mori K, Wilson K, Riggins GJ, Xia M, Grimaldi M, Jadhav A, Maloney DJ, Simeonov A.

PLoS One. 2016 Nov 8;11(11):e0166506. doi: 10.1371/journal.pone.0166506. eCollection 2016.

18.

Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.

Williamson T, Bai RY, Staedtke V, Huso D, Riggins GJ.

Oncotarget. 2016 Oct 18;7(42):68571-68584. doi: 10.18632/oncotarget.11851.

19.

A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models.

Martinez NJ, Rai G, Yasgar A, Lea WA, Sun H, Wang Y, Luci DK, Yang SM, Nishihara K, Takeda S, Sagor M, Earnshaw I, Okada T, Mori K, Wilson K, Riggins GJ, Xia M, Grimaldi M, Jadhav A, Maloney DJ, Simeonov A.

PLoS One. 2016 Aug 29;11(8):e0161486. doi: 10.1371/journal.pone.0161486. eCollection 2016. Erratum in: PLoS One. 2016 Nov 8;11(11):e0166506.

20.

Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines.

Binder ZA, Wilson KM, Salmasi V, Orr BA, Eberhart CG, Siu IM, Lim M, Weingart JD, Quinones-Hinojosa A, Bettegowda C, Kassam AB, Olivi A, Brem H, Riggins GJ, Gallia GL.

PLoS One. 2016 Mar 30;11(3):e0150271. doi: 10.1371/journal.pone.0150271. eCollection 2016.

21.

Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma.

Sawanyawisuth K, Tantapotinan N, Wongkham C, Riggins GJ, Kraiklang R, Wongkham S, Puapairoj A.

Ann Hepatol. 2016 Jan-Feb;15(1):71-81.

22.

EFFECT OF THE ANTIPARASITIC DRUG MEBENDAZOLE ON CHOLANGIOCARCINOMA GROWTH.

Sawanyawisuth K, Williamson T, Wongkham S, Riggins GJ.

Southeast Asian J Trop Med Public Health. 2014 Nov;45(6):1264-70.

PMID:
26466412
23.

The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model.

Pinto LC, Soares BM, Pinheiro Jde J, Riggins GJ, Assumpção PP, Burbano RM, Montenegro RC.

Toxicol In Vitro. 2015 Dec;29(8):2038-44. doi: 10.1016/j.tiv.2015.08.007. Epub 2015 Aug 24.

24.

Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.

Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, Gokaslan ZL, Groves ML, Jallo GI, Lim M, Olivi A, Quinones-Hinojosa A, Rigamonti D, Riggins GJ, Sciubba DM, Weingart JD, Wolinsky JP, Ye X, Oba-Shinjo SM, Marie SK, Holdhoff M, Agrawal N, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C.

Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9. doi: 10.1073/pnas.1511694112. Epub 2015 Jul 20.

25.

The role of piRNA and its potential clinical implications in cancer.

Assumpção CB, Calcagno DQ, Araújo TM, Santos SE, Santos ÂK, Riggins GJ, Burbano RR, Assumpção PP.

Epigenomics. 2015;7(6):975-84. doi: 10.2217/epi.15.37. Epub 2015 May 1. Review.

26.

Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.

Bai RY, Staedtke V, Wanjiku T, Rudek MA, Joshi A, Gallia GL, Riggins GJ.

Clin Cancer Res. 2015 Aug 1;21(15):3462-3470. doi: 10.1158/1078-0432.CCR-14-2681. Epub 2015 Apr 10.

27.

Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.

Staedtke V, Bai RY, Sun W, Huang J, Kibler KK, Tyler BM, Gallia GL, Kinzler K, Vogelstein B, Zhou S, Riggins GJ.

Oncotarget. 2015 Mar 20;6(8):5536-46.

28.

A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.

Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ.

J Neurooncol. 2015 Feb;121(3):479-87. doi: 10.1007/s11060-014-1672-2. Epub 2014 Dec 4.

29.

Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.

Larsen AR, Bai RY, Chung JH, Borodovsky A, Rudin CM, Riggins GJ, Bunz F.

Mol Cancer Ther. 2015 Jan;14(1):3-13. doi: 10.1158/1535-7163.MCT-14-0755-T. Epub 2014 Nov 5.

30.

Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.

Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, Gokaslan ZL, Riggins GJ, Wolinksy JP, Wood LD, Montgomery EA, Hruban RH, Kinzler KW, Papadopoulos N, Vogelstein B, Bettegowda C.

Nat Genet. 2014 Nov;46(11):1170-2. doi: 10.1038/ng.3116. Epub 2014 Oct 12.

31.

Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.

Bai RY, Staedtke V, Rudin CM, Bunz F, Riggins GJ.

Neuro Oncol. 2015 Apr;17(4):545-54. doi: 10.1093/neuonc/nou234. Epub 2014 Sep 24.

32.

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S.

Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982.

33.

NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.

Baia GS, Caballero OL, Ho JS, Zhao Q, Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A, Olivi A, Brem H, Burger P, Strausberg RL, Simpson AJ, Eberhart CG, Riggins GJ.

Cancer Immunol Res. 2013 Nov;1(5):296-302. doi: 10.1158/2326-6066.CIR-13-0029. Epub 2013 Aug 5.

34.

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

Aleyasin H, Karuppagounder SS, Kumar A, Sleiman S, Basso M, Ma T, Siddiq A, Chinta SJ, Brochier C, Langley B, Haskew-Layton R, Bane SL, Riggins GJ, Gazaryan I, Starkov AA, Andersen JK, Ratan RR.

Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. doi: 10.1089/ars.2013.5595.

35.

Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2014 Apr;2(4):371-9. doi: 10.1158/2326-6066.CIR-13-0088. Epub 2013 Nov 25.

36.

Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.

Yamashita AS, Baia GS, Ho JS, Velarde E, Wong J, Gallia GL, Belzberg AJ, Kimura ET, Riggins GJ.

J Neurooncol. 2014 May;118(1):83-92. doi: 10.1007/s11060-014-1422-5. Epub 2014 Mar 26.

37.

Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.

Silsirivanit A, Sawanyawisuth K, Riggins GJ, Wongkham C.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):388-96. doi: 10.1002/jhbp.68. Epub 2014 Feb 12. Review.

38.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

39.

Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.

Loilome W, Bungkanjana P, Techasen A, Namwat N, Yongvanit P, Puapairoj A, Khuntikeo N, Riggins GJ.

Tumour Biol. 2014 Jun;35(6):5357-67. doi: 10.1007/s13277-014-1698-2. Epub 2014 Feb 19.

40.

Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.

Binder ZA, Siu IM, Eberhart CG, Ap Rhys C, Bai RY, Staedtke V, Zhang H, Smoll NR, Piantadosi S, Piccirillo SG, Dimeco F, Weingart JD, Vescovi A, Olivi A, Riggins GJ, Gallia GL.

PLoS One. 2013 Oct 16;8(10):e75945. doi: 10.1371/journal.pone.0075945. eCollection 2013.

41.

Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.

Liu G, Bettegowda C, Qiao Y, Staedtke V, Chan KW, Bai R, Li Y, Riggins GJ, Kinzler KW, Bulte JW, McMahon MT, Gilad AA, Vogelstein B, Zhou S, van Zijl PC.

Magn Reson Med. 2013 Dec;70(6):1690-8. doi: 10.1002/mrm.24955. Epub 2013 Oct 7.

42.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

43.

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ.

Oncotarget. 2013 Oct;4(10):1737-47.

44.

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.

PMID:
23832540
45.

Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.

Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3519-28. doi: 10.1007/s13277-013-0930-9. Epub 2013 Jun 29.

PMID:
23812726
46.

Exomic sequencing of four rare central nervous system tumor types.

Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N.

Oncotarget. 2013 Apr;4(4):572-83.

47.

DDIT3, STT3A (ITM1), ARG2 and FAM129A (Niban, C1orf24) in diagnosing thyroid carcinoma: variables that may affect the performance of this antibody-based test and promise.

Carvalheira GM, Nozima BH, Riggins GJ, Cerutti JM.

Mod Pathol. 2013 Apr;26(4):611-3. doi: 10.1038/modpathol.2012.212. No abstract available.

48.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.

49.

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM.

Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.

50.

The Hippo signaling pathway and translational opportunities for brain cancers.

Baia GS, Caballero OL, Riggins GJ.

CNS Oncol. 2012 Nov;1(2):113-5. doi: 10.2217/cns.12.18. No abstract available.

Supplemental Content

Loading ...
Support Center